6-bromo-4-chloro-8-methyl quinazoline

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二氮杂萘
• 英文名称: 6-bromo-4-chloro-8-methyl quinazoline
• 英文别名: 6-bromo-4-chloro-8-methylquinazoline；6-Bromo-4-chloro-8-methylquinazoline
• 化学式: C₉H₆BrClN₂
• 分子量: 257.517
• InChiKey: AVNPVTTYPQZPRH-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.6
• 重原子数：
  13
• 可旋转键数：
  0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.11
• 拓扑面积：
  25.8
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  6-bromo-4-chloro-8-methyl quinazoline 在 potassium phosphate 、 tris-(dibenzylideneacetone)dipalladium(0) 、 氢溴酸 、 N,N-二异丙基乙胺 、 4,5-双二苯基膦-9,9-二甲基氧杂蒽 作用下， 以 N,N-二甲基乙酰胺 、 溶剂黄146 、 甲苯 为溶剂， 反应 13.0h， 生成 1-({2-[6-(3,3-difluoropyrrolidin-1-yl)-8-methylquinazolin-4-yl]-1,2,3,4-tetrahydroisoquinolin-7-yl}carbonyl)piperidin-4-amine
  参考文献：
  名称：

  [EN] QUINAZOLINE INHIBITORS OF PI3K
  [FR] INHIBITEURS QUINAZOLINES DE PI3K

  摘要：

  公开号：

  WO2014160177A3
• 作为产物：
  描述：

  2-氨基-5-溴-3-甲基苯甲酸 在 N,N-二甲基甲酰胺 作用下， 以 氯化亚砜 为溶剂， 反应 31.0h， 生成 6-bromo-4-chloro-8-methyl quinazoline
  参考文献：
  名称：

  Discovery, Synthesis, and Biological Evaluation of Thiazoloquin(az)olin(on)es as Potent CD38 Inhibitors

  摘要：

  A series of thiazoloquin(az)olinones were synthesized and found to have potent inhibitory activity against CD38. Several of these compounds were also shown to have good pharmacokinetic properties and demonstrated the ability to elevate NAD levels in plasma, liver, and muscle tissue. In particular, compound 78c was given to diet induced obese (DIO) C57Bl6 mice, elevating NAD > 5-fold in liver and >1.2-fold in muscle versus control animals at a 2 h time point. The compounds described herein possess the most potent CD38 inhibitory activity of any small molecules described in the literature to date. The inhibitors should allow for a more detailed assessment of how NAD elevation via CD38 inhibition affects physiology in NAD deficient states.

  DOI：

  10.1021/jm502009h

文献信息

• QUINAZOLINE DERIVATIVES AS TYROSINE KINASE INHIBITORS FOR THE TREATMENT OF CANCER
  申请人：Neupharma, Inc.

  公开号：EP4006035A1

  公开（公告）日：2022-06-01

  The present invention refers to quinazoline derivatives of formula (Ib): as kinase inhibitors for use in a method of treatment of cancer. An exemplary compound is e.g. example 1N-(3-(2,6-diphenylquinazolin-8-yl)phenyl)acrylamide

  本发明涉及式（Ib）的喹唑啉衍生物： 作为激酶抑制剂用于治疗癌症的方法。 一个示例化合物是例如 1N-(3-(2,6-二苯基喹唑啉-8-基)苯基)丙烯酰胺
• COMPOUNDS WHICH SPECIFICALLY BIND TO CD38 FOR USE IN THE TREATMENT OF NEURODEGENERATIVE AND INFLAMMATORY DISEASES
  申请人：ENCEFA

  公开号：EP3658586A1

  公开（公告）日：2020-06-03
• [EN] COMPOUNDS WHICH SPECIFICALLY BIND TO CD38 FOR USE IN THE TREATMENT OF NEURODEGENERATIVE AND INFLAMMATORY DISEASES<br/>[FR] COMPOSÉS SE LIANT DE MANIÈRE SPÉCIFIQUE À CD38 POUR UNE UTILISATION DANS LE TRAITEMENT DE MALADIES NEURODÉGÉNÉRATIVES ET INFLAMMATOIRES
  申请人：ENCEFA

  公开号：WO2019020643A1

  公开（公告）日：2019-01-31

  The present invention relates to a compound, which specifically binds to CD38, for use as a medicament in the prevention and/or treatment of a neurodegenerative disease and/or an inflammatory disease, by the opening of NAADP receptors Two Pore Channels TPC and/or TPC2, wherein said compound activates the opening of NAADP receptors Two Pore Channels TPC1 and/or TPC2.
• Discovery, Synthesis, and Biological Evaluation of Thiazoloquin(az)olin(on)es as Potent CD38 Inhibitors
  作者：Curt D. Haffner、J. David Becherer、Eric E. Boros、Rodolfo Cadilla、Tiffany Carpenter、David Cowan、David N. Deaton、Yu Guo、Wallace Harrington、Brad R. Henke、Michael R. Jeune、Istvan Kaldor、Naphtali Milliken、Kim G. Petrov、Frank Preugschat、Christie Schulte、Barry G. Shearer、Todd Shearer、Terrence L. Smalley、Eugene L. Stewart、J. Darren Stuart、John C. Ulrich

  DOI：10.1021/jm502009h

  日期：2015.4.23

  A series of thiazoloquin(az)olinones were synthesized and found to have potent inhibitory activity against CD38. Several of these compounds were also shown to have good pharmacokinetic properties and demonstrated the ability to elevate NAD levels in plasma, liver, and muscle tissue. In particular, compound 78c was given to diet induced obese (DIO) C57Bl6 mice, elevating NAD > 5-fold in liver and >1.2-fold in muscle versus control animals at a 2 h time point. The compounds described herein possess the most potent CD38 inhibitory activity of any small molecules described in the literature to date. The inhibitors should allow for a more detailed assessment of how NAD elevation via CD38 inhibition affects physiology in NAD deficient states.
• [EN] QUINAZOLINE INHIBITORS OF PI3K<br/>[FR] INHIBITEURS QUINAZOLINES DE PI3K
  申请人：EXELIXIS INC

  公开号：WO2014160177A3

  公开（公告）日：2015-05-14